Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (NASDAQ: AVIR) will present 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference and provided program and pipeline updates on Jan 8, 2026. The company reported $301.8 million cash and investments at Dec 31, 2025, with a cash runway expected through 2027. Atea is advancing a global Phase 3 program for a fixed-dose combination of bemnifosbuvir and ruzasvir for HCV: C-BEYOND (North America) is fully enrolled with >880 patients and topline results are expected mid-2026; C-FORWARD (outside North America) expects enrollment completion mid-2026 and topline results around year-end 2026. Phase 2 data showed 98% SVR12 (per-protocol) for an 8-week regimen. Atea selected AT-587 for HEV and anticipates initiating a Phase 1 study mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT in San Francisco.
Jean-Pierre Sommadossi, PhD, CEO and founder, and other Atea management will present. A live webcast will be available on the company's investor site at https://ir.ateapharma.com, with an archived webcast available for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR) completed enrollment of more than 880 treatment‑naïve patients in the North American C‑BEYOND Phase 3 trial evaluating a fixed‑dose combination of bemnifosbuvir and ruzasvir versus the comparator fixed‑dose sofosbuvir and velpatasvir regimen.
C‑BEYOND enrolled at ~120 sites in the US and Canada and topline results are expected mid‑2026. Atea is also advancing C‑FORWARD, a parallel Phase 3 outside North America targeting ~880 patients at ~120 sites, with enrollment expected mid‑2026 and topline results anticipated year‑end 2026. The bemnifosbuvir/ruzasvir regimen is oral once‑daily for 8 weeks (non‑cirrhotic) or 12 weeks (compensated cirrhosis), while the comparator is 12 weeks.
ReAlta Life Sciences (AVIR) appointed Howard Berman, Ph.D. as Executive Chairman effective immediately on November 25, 2025. The company said Dr. Berman brings more than 20 years of biopharma leadership across company formation, clinical development, strategic partnerships, and public-market execution.
ReAlta highlighted pegtarazimod's clinical data and safety profile across three life-threatening diseases and said the peptide platform targets complement and neutrophil-driven inflammation. Dr. Berman currently chairs Coya Therapeutics and serves on the board of Atea Pharmaceuticals.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO and founder Jean-Pierre Sommadossi, PhD, alongside other management team members, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET in Coral Gables, FL.
A live webcast will be available on the company website at https://ir.ateapharma.com, with an archived webcast accessible for at least 90 days following the event.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q3 2025 results and a business update highlighting progress in its global HCV Phase 3 program, new AASLD data, and a new HEV development program.
Key points: C-BEYOND expected fully enrolled by end-2025 with topline mid-2026; C-FORWARD enrollment expected complete mid-2026 with topline around end-2026. New data at AASLD support a dual mechanism for bemnifosbuvir and high bioavailability of the bemnifosbuvir/ruzasvir FDC, including dosing with famotidine. Two HEV leads (AT-587, AT-2490) are in IND-enabling studies with Phase 1 anticipated mid-2026.
Financials: $329.3M cash and marketable securities (Sept 30, 2025); Q3 R&D $38.3M, G&A $7.2M; Q3 net loss $42.0M or $0.53 per share. The company completed a $25M repurchase (7,673,793 shares), leaving 78,126,796 shares outstanding.
Atea Pharmaceuticals (Nasdaq: AVIR) presented new data at The Liver Meeting 2025 supporting its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) as a potential best-in-class, short-duration HCV regimen. Key findings include a modeled time to cure of ~7–8 weeks, Phase 2 SVR12 of 98% in the per-protocol population and 95% regardless of adherence, a resistance analysis showing a high barrier to resistance, and Phase 1 data showing the FDC has high relative bioavailability and can be dosed with or without food or with famotidine. The commercial FDC is being used in the ongoing Phase 3 program. A virtual KOL investor panel is scheduled for Nov 13, 2025 at 10:00 AM ET.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET to report third quarter results for the period ended September 30, 2025 and provide a business update.
Participants may register for the live call, access the audio webcast under Events and Presentations on Atea's Investor Relations site at ir.ateapharma.com, or join by telephone using the provided U.S. and international dial‑in numbers and conference ID 10203461. An archive of the webcast will be posted about two hours after the call and will remain available for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a virtual hepatitis C (HCV) key opinion leader panel on November 13, 2025 at 10:00 AM ET.
The panel will cover the HCV patient population, early diagnosis and treatment, public policy including test-and-treat, prospects for HCV eradication in North America, and what an optimized HCV therapy could offer prescribers and patients. Company management will discuss the HCV commercial market opportunity and Atea’s global Phase 3 program evaluating a bemnifosbuvir plus ruzasvir regimen. A live Q&A will follow; registration is required.
Panelists include: Jordan Feld MD MPH, Eric Lawitz MD, Anthony Martinez MD, and Nancy Reau MD.
Atea Pharmaceuticals (Nasdaq: AVIR) will present new data at The Liver Meeting® 2025 (Nov 7-11, Washington, DC) supporting the combination regimen of bemnifosbuvir and ruzasvir for hepatitis C. Three accepted abstracts cover multiscale Phase 2 modeling, a viral resistance analysis, and a Phase 1 food-effect/bioavailability study for a fixed-dose combination. Prior Phase 2 results (n=275) showed SVR12 98% in the per-protocol treatment-adherent population and 95% in the efficacy-evaluable population. A virtual KOL investor event is scheduled for Nov 13, 2025 at 10:00 AM ET.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
